Compare RSKD & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSKD | FTH |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.6M | 835.7M |
| IPO Year | 2021 | 2021 |
| Metric | RSKD | FTH |
|---|---|---|
| Price | $9.16 | $16.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $7.65 | ★ $55.38 |
| AVG Volume (30 Days) | ★ 2.1M | 307.5K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.01 | N/A |
| Revenue Next Year | $11.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $17.32 |
| 52 Week High | $9.18 | $42.14 |
| Indicator | RSKD | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 26.03 |
| Support Level | $4.33 | N/A |
| Resistance Level | N/A | $36.63 |
| Average True Range (ATR) | 0.47 | 2.18 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 94.81 | 2.92 |
Riskified Ltd offers an AI-powered e-commerce risk intelligence platform that identifies the individual behind each online interaction for legitimacy, helping merchants (its customers) eliminate risk and uncertainty from their business. The company's core product, the Chargeback Guarantee, automatically approves or declines online orders with performance levels that vary in accordance with its merchants' priorities. Additionally, it offers other products that mitigate similar e-commerce risks for those same merchants, including Policy Protect, Dispute Resolve, and Account Secure. Geographically, Riskified generates maximum revenue from the United States, and the rest from other regions of the Americas, Europe, the Middle East and Africa (EMEA), and the Asia-Pacific (APAC) region.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.